332 Studies Now Enrolling
Menu
Search
Medical Condition
- Show all (332)
- Addiction (4)
- Allergy, Asthma, & Immunology (1)
- Autoimmune Disorders (2)
- Blood Disorders (2)
- Bone & Muscle (2)
- Cancer (91)
- COVID-19 (Coronavirus) (8)
- Diabetes (6)
- Ear, Nose and Throat (6)
- Endocrine & Metabolic Disease (1)
- Gastrointestinal and Digestive Diseases (5)
- Hair and Skin Disorders (2)
- Healthy Volunteers (45)
- Heart Disease (21)
- Infectious Disease (12)
- Liver Disease (13)
- Lung Disease (2)
- Neurological Disorders (42)
- Nutrition (1)
- Obesity (7)
- Obstetrics & Gynecology (12)
- Pediatrics (21)
- Psychiatric Disorders (7)
- Rehabilitation (1)
- Stroke (1)
- Transplant (16)
- Vascular Conditions (1)
Displaying 1 - 17 of 17
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
This trial is testing two experimental drugs for HIV called VH3810109 (also called N6LS) and Fostemsavir (FTR). This trial is a Phase 1b study testing whether these drugs are safe to use in people and can be taken comfortably, as well as whether they may be helpful in eliminating HIV from the body. In this study, FTR will be given as a "helper drug…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
The main purpose of this study is to look at whether experimental study drugs are safe, whether your body can handle the effects, and whether these study drugs improve the body's response to human immunodeficiency virus (HIV) in people with HIV (PWH) who started antiretroviral therapy (ART) early after getting HIV-1. The study treatments include: a…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
Can we lower the chance of Diffuse Large B-cell Lymphoma (DLBCL) cancer growing or spreading by adding treatment to the usual therapy? This study is being done to find out if this approach is better or worse than the usual approach for DLBCL patients receiving chimeric antigen receptor (CAR) T-cell therapy. The usual approach for Relapsed/Refractory DLBCL…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to test the safety of drugs called tazemetostat and belinostat when administered together. This study tests different doses of the drugs to see which doses are safer for people. There will be between 21 and 48 people taking part in this study. There are two parts in this study, a dose escalation (dose finding) part and a dose…
Condition: Cancer / Lymphoma
Investigator: Nobuko Hijiya, MD
Status: Currently Recruiting
This Phase III trial investigates if the incorporation of immunotherapy will improve progression-free survival (PFS) and maintain overall survival (OS) while simultaneously minimizing long-term morbidity and treatment-related mortality by reducing exposure to radiotherapy and high cumulative chemotherapy doses. The study will enroll patients ages 5 to 60…
Condition: Cancer / Lymphoma
Investigator: Jennifer Amengual, MD
Status: Currently Recruiting
The purpose of this study is to compare the usual treatment alone to using tazemetostat or zanubrutinib plus the usual treatment for patients with relapsed or refractory large B-cell lymphoma (LBCL). Relapsed means the LBCL has returned after it responded to treatment. Refractory means the LBCL did not respond to earlier treatment. The addition of…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
This trial is testing an experimental treatment for HIV that is called CAB + RPV LA (long-acting cabotegravir and rilpivirine). CAB + RPV LA is a combination of drugs that is used to treat HIV (called antiretroviral therapy ART). It is currently approved in the US for the treatment of people living with HIV who are taking ART and whose viral load is already…
Condition: Cancer / Lymphoma
Investigator: Hua-Jay Cherng, MD
Status: Currently Recruiting
This research study is studying the phased variant enrichment and detection sequencing (PhasED-seq) circulating tumor DNA (ctDNA) assay in diffuse large B-cell lymphoma (DLBCL). The PhasED-seq assay is a blood test to measure tiny fragments of material released into the blood by lymphoma called circulating tumor DNA. The purpose of this study is to 1)…
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to see what effects, good and/or bad, the study drug, ST-001, has on you and your cancer, to find the best dose for treating your condition, and to see how safe ST-001 is for participants with your condition. This study will help us understand more about whether intravenous (injected into the vein) ST-001, will be a useful study…
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to evaluate long-term outcomes in transplant recipients with HIV who receive livers from donors with HIV compared to donors without HIV. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Condition: Infectious Disease / HIV
Investigator: Marcus Pereira, MD, MPH
Status: Currently Recruiting
The primary objective is to determine whether using hearts from HIV+ donors for HIV+ recipients is safe with regard to major transplant-related and HIV-related complications. The primary outcome is patient survival at one year. If you have any questions regarding this study, please contact the Transplant Clinical Research Center (TCRC).
Condition: Cancer / Lymphoma
Investigator: Barbara Pro, MD
Status: Currently Recruiting
The purpose of this study is to find out the safety, effectiveness, and blood levels of various doses of the study drug in participants with T-cell lymphoma that has not improved or has gotten worse. ONO-4685 is an experimental drug which is not approved by Health Authorities including the United States Food and Drug Administration (FDA). The study drug is…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental products, KITE-363 and KITE-753, are safe and effective in treating relapsed and/or refractory B-cell lymphoma. Participants will receive either KITE-363 or KITE-753 one time through intravenous (IV) infusion. The experimental treatment would involve removing some of your immune cells, genetically…
Condition: Cancer / Lymphoma
Investigator: Ran Reshef, MD
Status: Currently Recruiting
The purpose of this study is to find out if the experimental product, axi-cel, is safe and effective in treating your lymphoma, compared to standard of care (SOC) therapy (chemotherapy), which includes either R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone) or DA EPOCH R (dose-adjusted etoposide, prednisone, vincristine,…
Condition: Infectious Disease / HIV
Investigator: Rebecca Schnall, PhD, RN
Status: Currently Recruiting
****The WiseApp in Spanish Study is looking for Spanish-speaking People Living with HIV Residing in the NYC Area**** Are you living with HIV? Are you 18 years or older? Are you a Spanish speaker? Do you own a smartphone? Are you interested in learning more about your health? We are conducting a study at Columbia University School of Nursing to learn more…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
Do you identify as a woman or transgender person, or do you have a non-binary gender identity? Has a medical provider ever diagnosed you with a sexually transmitted infection or recommended PrEP/another HIV prevention method? We are conducting a study to understand attitudes and preferences regarding HIV prevention methods among people who do not have HIV.…
Condition: Infectious Disease / HIV
Investigator: Magdalena Sobieszczyk, MD
Status: Currently Recruiting
We are looking for individuals 18 to 60 years old who are interested in learning more about HIV prevention and biomedical research studies. We will ask you to complete a brief questionnaire to find out if we can schedule you for a one-on-one, 1.5-hour education visit to learn about the research we do. The education visit will help you decide if you want to…
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website,
you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the
Columbia University Website Cookie Notice.
I AGREE